Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda

• 1 Australian Institute of Health Innovation, University of New South Wales, Sydney, NSW.
• 2 Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, NSW.
• 3 Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW.

---

• 1. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared with assessment of other health technologies. Soc Sci Med 1997; 45: 563-581.
• 2. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3). Canberra: PBAC, 2008: 4.
• 3. Lopert R, Henry D. The Pharmaceutical Benefits Scheme: economic evaluation works . . . but is not a panacea. Aust Prescr 2002; 25: 126-127.
• 4. Harvey KJ, Day RO, Campbell WG, Lipworth W. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med J Aust 2011; 194: 567-568. <MJA full text>
• 5. Grogan K. Australia gives green light to Bayer/Regeneron's Eylea. PharmaTimes Online 2012; 8 Mar. http://www.pharmatimes.com/Article/ 12-03-08/Australia_gives_green_light_to_Bayer_Regeneron_s_Eylea.aspx (accessed Mar 2012).
• 6. Nordqvist C. VEGF Trap-Eye for wet age-related macular degeneration unanimously approved by FDA panel. Bexhill-on-Sea, UK: Medical News Today, 2011. http://www.medicalnewstoday.com/articles/228931.php (accessed Jan 2012).
• 7. Walley T. Health technology assessment in England: assessment and appraisal. Med J Aust 2007; 187: 283-285. <MJA full text>
• 8. Husereau D, Boucher M, Noorani H. Priority setting for health technology assessment at CADTH. Int J Technol Assess Health Care 2010; 26: 341-347.
• 9. Australian Government Department of Health and Ageing. Alternative arrangements for medicines. Other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS). Life Saving Drugs Program. 2011. http://www.health.gov.au/lsdp (accessed Mar 2012).
• 10. O’Malley SP, Jordan E. Horizon scanning of new and emerging medical technology in Australia: its relevance to Medical Services Advisory Committee health technology assessments and public funding. Int J Technol Assess Health Care 2009; 25: 374-382.
• 11. Morgan S, Boothe K. Prescription drug subsidies in Australia and New Zealand. Aust Prescr 2010; 33: 2-4.